NFL Biosciences SAS Market Cap ($5.23 Million)
Market Cap & Net Worth: NFL Biosciences SAS (ALNFL)
NFL Biosciences SAS market cap. NFL Biosciences SAS (PA:ALNFL) has a market capitalization of $5.23 Million (€4.47 Million) as of November 15, 2026. Listed on the PA stock exchange, this France-based company holds position #28502 globally and #528 in its home market, demonstrating a 3.37% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying NFL Biosciences SAS's stock price €0.35 by its total outstanding shares 12672242 (12.67 Million). Also see how efficiently does NFL Biosciences SAS generate cash for how efficiently the company converts equity into cash flow.
NFL Biosciences SAS Market Cap History (2021–2026)
NFL Biosciences SAS market cap history from 2021 to 2026. Data shows change from $35.56 Million to $5.23 Million (-35.55% CAGR). Check ALNFL stock price for real-time trading data and today's change.
NFL Biosciences SAS Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how NFL Biosciences SAS's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ALNFL net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
634476.30x
NFL Biosciences SAS's market cap is 634476.30 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $35.56 Million | $39.00 | -$978.24K | 911703.55x | N/A |
| 2023 | $21.33 Million | $200.01K | -$3.75 Million | 106.66x | N/A |
| 2024 | $29.19 Million | $46.00 | -$2.08 Million | 634476.30x | N/A |
Competitor Companies of ALNFL by Market Capitalization
Companies near NFL Biosciences SAS in the global market cap rankings as of November 15, 2026. Also see ALNFL total asset value for a full breakdown of the balance sheet.
Key companies related to NFL Biosciences SAS by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #286 globally with a market cap of $93.55 Billion USD.
- Moderna Inc (NASDAQ:MRNA): Ranked #304 globally with a market cap of $90.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $69.66 Billion USD ( AU$98.45 Billion AUD).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $538.60 |
| #286 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $93.55 Billion | $955.47 |
| #304 | Moderna Inc | NASDAQ:MRNA | $90.38 Billion | $223.37 |
| #412 | CSL Ltd | AU:CSL | $69.66 Billion | AU$202.92 |
Market Capitalization of NFL Biosciences SAS (2021–2026)
Market capitalization of NFL Biosciences SAS from 2021 to today. Between 2021 and today, NFL Biosciences SAS's market cap moved from $35.56 Million to $ 5.23 Million, with a yearly change of -35.55%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €5.23 Million | -70.03% |
| 2025 | €17.45 Million | -40.20% |
| 2024 | €29.19 Million | +36.81% |
| 2023 | €21.33 Million | -26.72% |
| 2022 | €29.11 Million | -18.12% |
| 2021 | €35.56 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 15th, 2026 the market cap of NFL Biosciences SAS was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.23 Million USD |
| MoneyControl | $5.23 Million USD |
| MarketWatch | $5.23 Million USD |
| marketcap.company | $5.23 Million USD |
| Reuters | $5.23 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About NFL Biosciences SAS
NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company's pipeline includes NFL-101, a drug candidate for smoking cessation, currently under Phase 2b clinical trials; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding… Read more